Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Impact of Additional Cytogenetic Abnormalities and Variant t(9;22) at Diagnosis on Prognosis of Childhood Chronic Myelogenous Leukemia : The Experience of the International Registry for CML in Children and Adolescents (I-CML-Ped Study)

Frédéric Millot, MD, Joelle Guilhot, PhD, Meinolf Suttorp, MD, Pietr Sedlacek, MD, Eveline S.J.M. de Bont, MD PhD, Chi Kong Li, MD, Krzysztof Kalwak, MD PhD, Birgitte Lausen, MD, Culic Srdjana, MD, Marie-Francoise Dresse, MD, Andrea Biondi, André Baruchel, MD, Françoise Brizard, MD

Blood (2014) 124 (21): 3137.

https://doi.org/10.1182/blood.V124.21.3137.3137

Published: 2014

Journal Articles

The Experience of the International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped Study): Pronostic Consideration

Frédéric Millot, MD, Joelle Guilhot, PhD, Meinolf Suttorp, MD, Petr Sedlacek, MD Prof., Eveline S.J.M. de Bont, MD PhD, Chi Kong Li, MD, Krzysztof Kalwak, MD PhD, Birgitte Lausen, MD, Culic Srdjana, MD, Marie-Francoise Dresse, MD, Andrea Biondi, Andre Baruchel

Blood (2014) 124 (21): 521.

https://doi.org/10.1182/blood.V124.21.521.521

Published: 2014

Journal Articles

Impairment of Longitudinal Growth By Tyrosine Kinase Inhibitor (TKI) Treatment - Data from a Large Pediatric Cohort with Chronic Myeloid Leukemia (CML)

Josephine Tabea Tauer, PhD, Christina Nowasz, Petr Sedlacek, MD Prof., Eveline S.J.M. de Bont, MD PhD, Olga V. Aleinikova, MD Prof., Meinolf Suttorp, Prof. Dr., All Participants of Trial CML-PAED II

Blood (2014) 124 (21): 522.

https://doi.org/10.1182/blood.V124.21.522.522

Published: 2014

Journal Articles

Pharmacokinetic Results Of a Feasibility and Phase II Study (ITCC 021) On Bortezomib (BTZ) In Pediatric Relapsed ALL: Lack Of Significant Penetration Of BTZ In The Cerebrospinal Fluid

Gertjan Kaspers, MD, PhD, Ron Mathot, PharmD PhD, Satianand Ramnarain, MSc, Denise Niewerth, MSc, Franco Locatelli, MD, PhD, Eveline S.J.M De Bont, MD, PhD, Franca Fagioli, MD, Pierre Rohrlich, MD, Arend von Stackelberg, Michel Zwaan

Blood (2013) 122 (21): 1439.

https://doi.org/10.1182/blood.V122.21.1439.1439

Published: 2013

Journal Articles

Identification of distinct protein Signatures Associated with genetic Abnormalities In Acute Lymphoblastic Leukemia

Roland P. Kuiper, PhD, Blanca Scheijen, PhD, Agata Pastorczak, MD, Simon V. van Reijmersdal, BSc, Deborah A. Thomas, MD, Niangxiang Zhang, PhD, Kevin R. Coombes, PhD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Eveline S.J.M De Bont, MD, PhD, Frank N. van Leeuwen, PhD, Steven M. Kornblau, MD

Blood (2013) 122 (21): 1313.

https://doi.org/10.1182/blood.V122.21.1313.1313

Published: 2013

NARROW

Impact of Additional Cytogenetic Abnormalities and Variant t(9;22) at Diagnosis on Prognosis of Childhood Chronic Myelogenous Leukemia : The Experience of the International Registry for CML in Children and Adolescents (I-CML-Ped Study)

The Experience of the International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped Study): Pronostic Consideration

Impairment of Longitudinal Growth By Tyrosine Kinase Inhibitor (TKI) Treatment - Data from a Large Pediatric Cohort with Chronic Myeloid Leukemia (CML)

Pharmacokinetic Results Of a Feasibility and Phase II Study (ITCC 021) On Bortezomib (BTZ) In Pediatric Relapsed ALL: Lack Of Significant Penetration Of BTZ In The Cerebrospinal Fluid

Identification of distinct protein Signatures Associated with genetic Abnormalities In Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Impact of Additional Cytogenetic Abnormalities and Variant t(9;22) at Diagnosis on Prognosis of Childhood Chronic Myelogenous Leukemia : The Experience of the International Registry for CML in Children and Adolescents (I-CML-Ped Study)

The Experience of the International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped Study): Pronostic Consideration

Impairment of Longitudinal Growth By Tyrosine Kinase Inhibitor (TKI) Treatment - Data from a Large Pediatric Cohort with Chronic Myeloid Leukemia (CML)

Pharmacokinetic Results Of a Feasibility and Phase II Study (ITCC 021) On Bortezomib (BTZ) In Pediatric Relapsed ALL: Lack Of Significant Penetration Of BTZ In The Cerebrospinal Fluid

Identification of distinct protein Signatures Associated with genetic Abnormalities In Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only